Technology Opportunities

Refine / Revise Search50 technologies found
page 1 of 3
A Diagnostic tool for specific bacterial detection (Pseudomonas aeruginosa) (Yeda)
Summary Highlights Pseudomonas aeruginosa bacteria are common pathogens that are difficult to treat and are therefore critical to diagnose early when involved in infections. The commonly used method for confirming a P. aeruginosa infection is cultural inoculation, which takes 2-3 days to ...
Scientific Contact: Noam Sobel
More Details...
A Method in Improving Survival and Expansion of Hematopoietic Stem Cells (Yeda)
Summary hematopoietic cells. HSCs have the capacity to both self-renew and to differentiate, and they migrate from the bone marrow to the blood upon demand. Since HSCs can differentiate to a variety of cell types, including immune system cells, they have a huge therapeutic potential. Indeed, ...
Scientific Contact: Idit Shachar
More Details...
A Novel Approach for Controlling Gene Expression (Arbirtium - a Novel approach) (Yeda)
Summary One of the challenges in the areas of synthetic biology and its clinical applications, is the capacity to control the induction of different genes, whether for the purpose of activating genetic circuits or inducing the expression of a specific protein. Present approaches are limited to ...
Scientific Contact: Rotem Sorek
More Details...
A Novel Approach for Treating Cancer and Collagen-Associated Diseases by Using Anti-LOXL-2 Antibody (Yeda)
Summary Disruption to the Extra-Cellular Matrix (ECM) is associated with many pathological conditions, such as various cancer types and tissue fibrosis, and also correlates with high tumor malignancy. Therefore, controlling ECM composition and morphology is considered a potential treatment for ...
Scientific Contact: Irit Sagi
More Details...
A Novel Method for Detecting Activation of Necroptosis via Exosome Analysis (Yeda)
Summary Numerous medical conditions are related to inflammation, such as pancreatitis, psoriasis, inflammatory bowel disease, atherosclerosis, neurodegeneration, and more. However, determination of inflammation in the body, especially at early stages of a pathology is difficult to assess. ...
Scientific Contact: David Wallach
More Details...
A Novel Method for Treating Drug-Resistant Lung Cancer Using a Combination of Antibodies (Yeda)
Summary A novel method for treating tyrosine kinase inhibitor (TKI)-resistant cancer, by using a combination of three different antibodies. Lung cancer is known as one of the most fatal forms of cancer. Notably, standard treatments for other cancer types (e.g. TKIs and mAbs), have shown only a ...
Scientific Contact: Yosef Yarden
More Details...
A Novel Method of Preventing or Treating Secondary Infections by Inhibition of Membrane Type I Matrix-Metalloproteinase-1 (Yeda)
Summary A novel method of preventing secondary infections, by inhibition of membrane type I matrix-metalloproteinase-1 (MT1-MMP), which reduces degradation of the extra-cellular matrix. Pathogens that infect the respiratory system are the cause of some of the most dangerous infections, ...
Scientific Contact: Irit Sagi
More Details...
A Novel Method of Treating Cancer by Targeting EGFR Ligand Amphiregulin (Yeda)
Summary A novel method for treating ovarian cancer by intercepting the EGFR ligand amphiregulin, when elevated expression levels are found in a patient. Ovarian cancer represents a relatively common type of cancer that affects women. However, the primary therapeutic option for ovarian cancer ...
Scientific Contact: Yosef Yarden
More Details...
A Novel Target for Inducing Myelinating Activity of Oligodendrocytes (Yeda)
Summary The proper functioning of the central nervous system (CNS) depends on effective communication between different neurons. A fundamental process ensuring said communication is myelination, which acts to insulate projections of neurons (axons) to ensure efficient transmittance of ...
Scientific Contact: Elior Peles
More Details...
A Novel Technique to Produce Large Quantities of Therapeutic T cells (Yeda)
Summary Culturing and expanding T cells ex-vivo, while retaining their functionality, is an essential factor for the development of cutting-edge immunotherapies. A major problem frequently faced by physicians is the low number of T cells available for adoptive immunotherapy, and the difficulty ...
Scientific Contact: Benjamin Geiger
More Details...
A TACE inhibitor (ADAM17) (Yeda)
Summary New generation of superior nature-inspired therapeutics for treating inflammation.Inflammation is characterized by elevated levels of TNF-?. Neutralizing TNF-? activity was shown to be beneficial for patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis ...
Scientific Contact: Irit Sagi
More Details...
Acquisition of Multidimensional NMR Spectra in a Single Scan (Yeda)
Summary A method to significantly shorten acquisition times of high-quality MRI images. Multidimensional nuclear magnetic resonance (NMR) is used nowadays in many applications (e.g., discovery of new pharmaceutical drugs, characterization of new catalysts, and investigation of the structure and ...
Scientific Contact: Lucio Frydman
More Details...
Affinity Maturated T-Cell Receptor (Yeda)
Summary Immunotherapy, that is the use of the immune system to treat cancer, is currently a leading candidate in the combat against cancer. Unlike the toxic effects of both chemotherapy and radiation, immunotherapy is considered to have mild side effects due to its ability to differentiate ...
Scientific Contact: Rachel Lea Eisenbach
More Details...
Antibodies directed to ErbB ligandsfor treating cancer (Yeda)
Summary A tailor-made strategy for cancer treatment. The ErbB family of tyrosine kinase receptors and their ligands play important roles in development and tissue remodeling throughout adulthood. ErbB proteins are involved in several types of human cancer. Clinical studies indicate that ...
Scientific Contact: Yosef Yarden
More Details...
Antibody Combinations in Treating Cancer (Yeda)
Summary Improved immunotherapy for breast cancer. Monoclonal antibodies (mAbs) to ErbB-2/HER2 growth factor receptor, or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low ...
Scientific Contact: Yosef Yarden
More Details...
Biological treatment for pancreatic cancer (MMP7 mAb) (Yeda)
Summary Although early programs targeting MMPs (matrix metalloproteins) were largely unsuccessful due to adverse side effects, they remain a viable and highly desirable therapeutic target. The main obstacle in the attempts to target MMPs is the ability to selectively target individual family ...
Scientific Contact: Irit Sagi
More Details...
CD84 - a Novel Regulator of B-CLL Survival (Yeda)
Summary New protein as a target to treat B cell-related cancer.Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about ...
Scientific Contact: Idit Shachar
More Details...
Cholesterol Antibodies (Yeda)
Summary Description: Monoclonal antibodies specific for cholesterol/ceramide-rich domains (clones 405F, 14F, 499F) and cholesterol micro-domains (clones 36A1, 5881) in cell membranes. Originally raised against an artificial monolayer of lipid mixtures in, and were shown to specifically label ...
Scientific Contact: Lia Addadi
More Details...
CO2 Fixation with Bioengineered Microorganisms (Yeda)
Summary Biomass production by plants and other photosynthetic organisms involves carbon fixation, the process of incorporating inorganic carbon dioxide into organic compounds. Currently carbon fixation by plants and other photosynthetic organisms is the limiting factor in biomass ...
Scientific Contact: Ron Milo
More Details...
Compositions for inhibitors of QSOX1 (Yeda)
Summary A potential target for anticancer drug design.Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of ...
Scientific Contact: Deborah Fass
More Details...
ITTN's partners are affiliated with some of the world's leading Educational and Research Institutions.